NEW OPTION FOR MANAGEMENT OF HIGH-RISK SOFT TISSUE SARCOMA OF THE LIMB International, multi-centre sarcoma trial shows benefits of integrating immunotherapy with radiotherapy and surgery
The Australia and New Zealand Sarcoma Association (ANZSA) is the peak body for the sarcoma community. ANZSA aims to improve outcomes for sarcoma patients through research, education and awareness of sarcomas and related tumours.
ANZSA fosters effective collaborations across multi-disciplinary teams (MDT), which comprise of specialist health professionals (including pathologists, radiologists, surgeons, radiation oncologists, medical oncologists and paediatric oncologists) working together to discuss sarcoma and related tumours cases, and how to best manage treatment and care.
Professor Angela Hong MBBS, MMed, PhD, FRANZCR is the co-Chair of ANZSA’s Scientific Advisory Committee and a Professor at Sydney Medical School of the University of Sydney. She is a radiation oncologist and has been a member of the Multidisciplinary Bone and Soft Tissue Tumour Clinic at Royal Prince Alfred Hospital/Chris O’Brien Lifehouse for the past 15 years.
As a clinician scientist, her research focuses on developing innovative radiation therapy technique and combination treatments to improve the outcome for patients with sarcoma.
Professor Hong spoke to Australian Health Journal about sarcoma and a recently concluded international, multicentre trial, that could lead to a new potential option for patients grappling with high-risk sarcoma of the limb.
Soft tissue sarcoma, a rare aggressive cancer originating in connective tissues, can affect both children and adults. It is particularly challenging to conduct clinical trials due to its rarity, However a recently concluded international collaborative Phase II clinical trial SARC032 has shown groundbreaking findings into the advantages of Immunotherapy for patients with high-risk soft tissue sarcoma of the limb
The trial was led by the Sarcoma Alliance Research Collaboration (SARC) in the United States and the Australia and New Zealand Sarcoma Association (ANZSA) in Australia. The Australian participating sites in the trial were Peter MacCallum Cancer Centre, Chris O’Brien Lifehouse and Princess Alexandra Hospital.
SARC032 is the first completed randomised clinical trial of its kind and has demonstrated compelling evidence to integrate immunotherapy, with the standard treatment regimen of radiotherapy and surgery for patients with grade 2 or 3, stage III soft tissue sarcoma of the limb.
Professor Angela Hong, Australia’s Principal Investigator for the trial, believes these results will be beneficial for patients for this specific stage of sarcoma.
“This is a significant milestone. The integration of immunotherapy into standard treatment protocols heralds a new era in sarcoma management, offering patients and clinicians a potent tool in the battle against this formidable disease.”
-
Nurse recognised for reducing hospital waste
A nurse who started a charity from a granny flat in her parent’s backyard to reduce hospital waste has taken out one of the Australian nursing profession’s most prestigious honours.
-
Continuity of Care under COVID-19
Series 3, Episode 1
Under the COVID-19 pandemic, the Australian Healthcare system has handled the public health crisis by monitoring and responding to challenges in supply chains, testing & tracing of new infections and stock piling of essential equipment.
The public has largely responded by practising social distancing, understanding how hand hygiene can spread contagion and recently installing the COVIDSafe mobile application. Public health messaging has been largely effective and literacy improve, to combat the dangers of misinformation.
To open up access to medical advice during the pandemic, in March the Australian government issued MBS item codes for telehealth consultations, for advanced practice nurses as well as GPs and other specialists.
According to AMA President Dr Tony Bartone, as of mid-May 2020, around 10 million Medicare-funded telehealth services have been provided, either over the phone or via video, a significant majority of which have been provided by GPs and other specialists since the Medicare telehealth items were introduced in March.
However in recent months, the health system has mounting concerns on:
- a reduction in general practice visits for testing, investigation or immunisation
- lower rates of elective procedures resuming since being halted
- reduction in laboratory testing
- reduction in treatments and diagnosis of chronic and acute conditions
- access to, and continuing to take medications
Those with pre-existing conditions have been urged to keep appointments and routine treatments to maintain their health.
Industry has taken action such as the newly formed Continuity of Care Collaboration (CCC). The 15 health organisations forming CCC are an Australian first national communication collaboration of Peak Bodies, Industry and Healthcare Organisations coming together to stress the importance for people to continue monitoring their health and maintaining their regular care.
This Australian Health Journal episode on the continuity of care was produced with commentary from the following health industry associations and organisations: APNA – Australian Primary Health Care Nurses Association, RACGP, Medical Technology Association of Australia (MTAA), West Cessnock Medical Practice, Consumers Health Forum of Australia, Medicines Australia
-
Australian Healthcare and Hospitals Association (AHHA) Blueprint Refresh Roundtable
AHHA’s Blueprint Refresh Roundtable brings together AHHA members and other Australian health leaders to evaluate the progress made to date against Healthy people, healthy systems and to tease out key policy issues that need to be addressed in order to implement outcomes-focused, value-based care in Australia.
